EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in Japan

Eiji Nakata iD, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, Shinji Kohsaka

Cancer Medicine · 2024-06 · 13 (12)

DOI: 10.1002/cam4.7351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 25.06.2024. Verfasst von Eiji Nakata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Receptor, trkA, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Yakuhin, Ltd., Bayer Yakuhin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Members of the neurotrophic tropomyosin receptor kinase ( NTRK ) gene family, NTRK1 , NTRK2 , and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which are oncogenic drivers in various solid tumors.

Methods

This study investigated the prevalence of NTRK fusion genes and identified fusion partners in Japanese patients with solid tumors recorded in the Center for Cancer Genomics and Advanced Therapeutics database of comprehensive genomic profiling test.

Results

In the analysis population ( n = 46,621), NTRK fusion genes were detected in 91 patients (0.20%). The rate was higher in pediatric cases (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncogene Proteins, FusionReceptor, trkANeoplasmsHumansJapanMaleFemaleChildAdultReceptor, trkCAdolescentReceptor, trkBPrevalenceYoung AdultMiddle AgedChild, PreschoolAgedMembrane Glycoproteins

Stichwörter der Autor:innen

comprehensive genomic profilingneurotrophic tropomyosin receptor kinase (NTRK) gene fusionnext‐generation sequencingsolid tumors

Substanzen

Oncogene Proteins, FusionReceptor, trkAReceptor, trkCReceptor, trkBNTRK1 protein, humanNTRK3 protein, humantropomyosin-related kinase-B, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Okayama University, Okayama, Japan.
  • Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.
  • National Cancer Center Research Institute, Tokyo, Japan.

ORCID-Profile: Eiji Nakata

Förderung

  • Bayer Yakuhin, Ltd.
  • Bayer Yakuhin

Zitieren

APA

Nakata, E., Osone, T., Ogawa, T., Taguchi, T., Hattori, K., & Kohsaka, S. (2024). Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in Japan. Cancer Medicine, 13(12). https://doi.org/10.1002/cam4.7351

Vancouver

Nakata E, Osone T, Ogawa T, Taguchi T, Hattori K, Kohsaka S. Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in Japan. Cancer Medicine. 2024;13(12). doi:10.1002/cam4.7351

BibTeX
@article{Nakata2024,
  author = {Nakata, Eiji and Osone, Tatsunori and Ogawa, Toru and Taguchi, Tomoyuki and Hattori, Kana and Kohsaka, Shinji},
  title = {Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in Japan},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {12},
  doi = {10.1002/cam4.7351}
}
Kostenlos starten →